Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 284
- 试验地点
- 1
- 主要终点
- Urination regularity
研究概览
简要总结
This is a double-blind, randomized, double-dummy, comparative study in parallel groups of subjects presenting with recurrent cystitis (≥2 episodes within the past 6 months). Subjects will be randomized and treated with one of two presentations of urinary antiseptics containing methenamine and methylthioninium for three days, followed by three days of antibiotic therapy as determined by urine culture and antibiogram. This study aims to assess the efficacy and safety of each treatment.
详细描述
This is a double-blind, randomized, double-dummy, comparative study in parallel groups of subjects presenting with recurrent cystitis (≥2 episodes within the past 6 months). After initial evaluations including urine culture and antibiogram, a total of 284 subjects will be randomized and treated with one of two presentations of urinary antiseptics containing methenamine and methylthioninium for six days. After three days of treatment, subjects will return to the study center and antibiotic therapy based on the results of the urine culture and antibiogram will be initiated for each subject, to be continued for the remaining three days of the treatment period. Efficacy assessments will include the UTISA (Urinary Tract Infection Symptoms Assessment Questionnaire) together with a global assessment by the investigator. Safety assessments will include monitoring of adverse events and laboratory tests carried out at each of the three study visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of both sexes, age ≥18
- •Clinical diagnosis of recurrent cystitis (≥ 2 episodes in the past 6 months)
- •Female subject of reproductive age not pregnant, agrees to use birth control during study period
- •Subject has read, understood, signed and dated informed consent document
排除标准
- •History of nephritis or kidney stones
- •History of hepatic or gastrointestinal disease
- •Female subjects: pregnancy or breastfeeding
- •History of anatomical alterations contributing to recurring cystitis on imaging exams
- •Hypersensitivity to any component of study drug
研究组 & 干预措施
Methenamine + Methylthioninium
Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
干预措施: Methenamine + Methylthioninium (Drug)
Methenamine + Methylthioninium
Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
干预措施: Antibiotics (Drug)
Methenamine+Methylthioninium+Acriflavine+Atropa belladona
Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
干预措施: Methenamine + Methylthioninium + Acriflavine + Atropa belladona (Drug)
Methenamine+Methylthioninium+Acriflavine+Atropa belladona
Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
干预措施: Antibiotics (Drug)
结局指标
主要结局
Urination regularity
时间窗: Following three days of treatment with urinary antiseptics
Percentage of subjects presenting improvement in cystitis symptoms in the "Urination Regularity" domain of the UTISA at Visit 2.
次要结局
- Problems with Urination at Visit 3(After 6 days of treatment)
- Total UTISA score(From pretreatment to final visit, total of 6 days of treatment)
- Adverse events(From pretreatment to final visit, total of 6 days of treatment)
- UTISA question # 9(At Visit 2, after 3 days of treatment)
- Blood in Urine at Visit 3(After 6 days of treatment)
- Problems with Urination at Visit 2(After 3 days of treatment)
- Pain Associated with UTI at Visit 3(After 6 days of treatment)
- Blood in Urine at Visit 2(After 3 days of treatment)
- Pain Associated with UTI at Visit 2(After 3 days of treatment)
研究者
Carlos Pereira Nunes
Professor of Internal Medicine
Fundação Educacional Serra dos Órgãos
